ABSTRACT:
Olaparib and Bevacizumab are anti-cancer agents. A new stability indicating RP-HPLC technique has been developed and validated for the simultaneous assay of Olaparib and Bevacizumab using Inertsil ODS column with UV detection at 258 nm within a run time of 6 minutes where Olaparib was eluted at 2.336 min and that of Bevacizumab at 4.873 min. Linearity was observed over the concentration range 37.50-225 µg/mL for Olaparib and 6.25-37.50 µg/mL for Bevacizumab respectively and the regression equations were found to be y=16815.19x+22410.75 and y=14512.58x+2387.04 for Olaparib and Bevacizumab respectively. The LOD was found to be 0.9 µg/ml and 0.1500 µg/mL whereas the LOQ was found to be 3.00 µg/mL and 0.5000 µg/mL for Olaparib and Bevacizumab respectively.
Cite this article:
Shanthi Priya DK, Mukthinuthalapati Mathrusri Annapurna. Stability indicating RP-HPLC method for the simultaneous estimation of Olaparib & Bevacizumab in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology. 2024; 17(2):910-4. doi: 10.52711/0974-360X.2024.00141
Cite(Electronic):
Shanthi Priya DK, Mukthinuthalapati Mathrusri Annapurna. Stability indicating RP-HPLC method for the simultaneous estimation of Olaparib & Bevacizumab in pharmaceutical dosage forms. Research Journal of Pharmacy and Technology. 2024; 17(2):910-4. doi: 10.52711/0974-360X.2024.00141 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-2-69
REFERENCES:
1. Bochum S, Berger S and Martens UM. Olaparib. Recent Results Cancer Res. 2018; 211: 217-233.
2. Kazazi-Hyseni F, Beijnen JH and Schellens JH. Bevacizumab. Oncologist. 2010; 15(8): 819-825.
3. Sousa F, Gonçalves VMF and Sarmento B. Development and validation of a rapid reversed-phase HPLC method for the quantification of monoclonal antibody Bevacizumab from polyester-based nanoparticles. J Pharm Biomed Anal. 2017; 142: 171-177.
4. Oliva A and labrés M. Validation of a size-exclusion chromatography method for Bevacizumab quantitation in pharmaceutical preparations: application in a biosimilar study. Separations 2019; 6(3): 43.
5. Chaudhary A, Tonk R, Dagur P, Dey S and Ghosh M. Stability indicating assay method for the quantitative determination of Olaparib in bulk and pharmaceutical dosage form. Turk J Pharm Sci. 2022; 19(5): 488-497.
6. Priyanka W, Preeti K, Smita G, Vijaya Kumar M, Raman Mohan S and Bhaskar V. Method development and validation for quantitative estimation of Olaparib in tablet dosage. World Journal of Pharmaceutical Research. 2021; 10(12): 2162-2174.
7. Daumar P, Robin D, Clemence D and Emmanuel M. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. J Pharm Biomed Anal. 2018; 152: 74-80.
8. Antima C, Rajiv D, Pankaj D and Sudhasatya D. Stability indicating assay method for the quantitative determination of Olaparib in bulk and pharmaceutical dosage form. Turk J Pharm Sci. 2022; 19(5): 488-497.
9. Kavitapu D, Arthanareeswari M, Devikala S, Arockia S, Tamil selvin M, Sudershan M and Pradeep Kumar G. New rapid stability indicating RP-UPLC method for the determination of Olaparib, its related substances and degradation products in bulk drug and dosage form. Materials Today: Proceedings. 2019; 2(14): 492-503.
10. Nijenhuis C.M, Lucas L, Rosing H, Schellens J.H, Beijnen J.H. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying Olaparib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 940: 121-125.
11. Ottria R, Ravelli A, Miceli M, Casati S, Orioli M and Ciuffreda P. Quantitative characterization of Olaparib in nano delivery system and target cell compartments by LC-MS/MS. Molecules. 2019; 24(5): 989.
12. ICH Validation of analytical procedures: Text and methodology, Q2 (R1), International Conference on Harmonization, 2005.
13. ICH Q1A (R2) Stability testing of new drug substances and products (2003).